Susan J. Lewis, Pharm.D.
Associate Professor of Pharmacy Practice
Year started at UF: 2016
CONTACT INFORMATION
Office Location: Davis Street Building Room 131 E
Telephone: 419-434-5948
Email: slewis@findlay.edu
ACADEMIC CREDENTIALS
B.S., University of Toledo
Pharm.D., University of Toledo
Dr. Lewis received her Pharm.D. degree from the University of Toledo. She completed a Pharmacy Practice Residency at the University of Toledo Medical Center and a Critical Care Nephrology research fellowship at the University of Michigan. She currently practices at Mercy System St. Anne Hospital in Toledo as a clinical pharmacist focusing on an Antibiotic Stewardship Program. Her research interests include pharmacokinetics, antibiotics, and drug dosing in patients with renal disease.
Professional Affiliations
Ohio College of Clinical Pharmacy 2018-Present
American Academy of Colleges of Pharmacy 2016-Present
Ohio Pharmacists Association 2016-Present
American College of Clinical Pharmacy 2013-Present
American Society of Health-System Pharmacists 2013-Present
Infectious Diseases Society of America 2016-2018
American Society of Nephrology 2013-2016
Society of Critical Care Medicine 2013-2016
American Pharmacists Association 2011-2013
Ohio Pharmacists Association 2011-2013
Ohio College of Clinical Pharmacy 2012-2013
Journal & Book Chapter Reviewer
Pharmacotherapy Principle and Practice 6ed. Chapter 027 - Chronic and End-Stage Renal Disease
Seminars in Dialysis
Antimicrobial Agents and Chemotherapy
Pharmacotherapy
Journal of Clinical Pharmacy and Therapeutics
SAGE Open Medicine
Journal of Clinical Pharmacy and Therapeutics
International Journal of Environmental Research and Public Health
Frontiers
Journal of Pharmacy Technology
Infection and Drug Resistance
Infectious Disease
Journal of Critical Care
Medicina
Journal of Antimicrobial Chemotherapy
Pharmacy
Annals of Pharmacotherapy
American Association of Colleges of Pharmacy
American Society for Artificial Internal Organs
Kidney International
Clinical Pharmacology & Therapeutics
Expert Review of Clinical Pharmacology
Pharmacotherapy
Clinical Journal of the American Society of Nephrology
Critical Care Medicine
American Journal of Health-System Pharmacy
Peer Reviewed Articles
Domaleczny BJ, Lewis SJ, Richardson JL, Eid HR. Impact of Pharmacist Intervention to Deprescribe Inappropriate Aspirin Therapy in an Outpatient Anticoagulation Clinic at a Community Hospital. American Heart Journal Plus. 2022;17: 100165. doi:10.1016/j.ahjo.2022.100165. [published online]
Sember AM, LoFaso ME, Lewis SJ. Authors Comments. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy. J Criti Care. 2022;70:154059.
Sember AM, LoFaso ME, Lewis SJ. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy. J Crit Care. 2022;69:154011.
Lewis SJ, Bodenhorn D, Na EY, Jang SM. Comparison of antimicrobial dosing recommendations in patients receiving intermittent hemodialysis among drug information resources. J Clin Pharm Ther. 2022;47:628-635.
Gharibian KN, Lewis SJ, Heung M, Segal JH, Salama NN, Mueller BA. Telavancin Pharmacokinetics in Patients with Chronic Kidney Disease Receiving Hemodialysis. Journal of Antimicrobial Chemotherapy. 2021:77(1):174-180.
Lewis SJ, Nolin TD. New Vancomycin Dosing Guidelines for Hemodialysis Patients: Rationale, Caveats, and Limitation. Kidney360. 2021;2:1313-1315.
- Selected as one of top five best publication in 2021 from the journal
Lewis SJ, Mueller BA. “Evaluation of Contemporary Vancomycin Dosing in Patients with Chronic Hemodialysis : Development of a New Dosing Scheme Using Monte Carlo Simulation." J Clin Pharmaco 2021;6(2):211-223.
- Selected as Editor's choice for the journal issue
Hartman RE†, Rao P.S.S., Churchwell MD, Lewis SJ. Novel Therapeutic Agents for the Treatment of Diabetic Kidney Disease. Expert Opin Investig Drugs 2020;29(11):1277-1293.
Jang SM, Lewis SJ, Mueller BA. Harmonizing Antibiotic Regimens with Renal Replacement Therapy. Expert Rev Anti Infect Ther. 2020;18(9):887-895.
McGee EU, Samuel E, Boronea B, Dillard N, Milby MN, Lewis SJ. Quinolone Allergy. Pharmacy 2019;7(3).
Jang SM, Gharibian KN, Lewis SJ, Fissell WH, Tolwani AJ, Mueller BA. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. J Clin Pharmacol. October 2018;58(10):1254-65.
Lewis SJ*, Mueller BA. Development of a Vancomycin Dosing Approach for Critically Ill Patients Receiving Hybrid Hemodialysis Using Monte Carlo Simulation. SAGE Open Medicine. 2018;6:2050312118773257.
Shaw A, Charijamorn W, Lewis SJ, Mueller BA. Ex vivo Ceftolozane/Tazobactam Clearance During Continuous Renal Replacement Therapy. Blood Purif. February 2017;44(1):16-23.
Lewis SJ, Chaijamorn W, Shaw A, Mueller BA. In silico Trials using Monte Carlo Simulation to Evaluate Ciprofloxacin and Levofloxacin Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Renal Replacement Therapy. September 2016;2:45.
Lewis SJ, Kays MB, Mueller BA. Use of Monte Carlo Simulation to Determine Optimal Doripenem, Ertapenem, Imipenem and Meropenem Dosing Recommendations in Critically Ill Patients Receiving SHIFT Renal Replacement Therapy. J Clin Pharmacol. October 2016;56(10):1277-87.
Lewis SJ, Mueller BA. Antibiotic dosing in Acute Kidney Injury: Enough, but not too much. J Intensive Care Med. March 2016; 31(3):164-76.
Lewis SJ, Switaj L, Mueller BA. Tedizolid adsorption and transmembrane clearance during in-vitro continuous renal replacement therapy (CRRT). Blood Purif. June 2015;40(1):66-71.
Lewis SJ, Mueller BA. Antibiotic dosing in critically ill patients receiving CRRT: Underdosing is overprevalent. Semin Dial. September-October 2014;27(5):441-445.
Book Chapters
Lewis SJ, Churchwell MD. “Vancomycin Area Under the Concentration-Time Curve Threshold Associated with Nephrotoxicity." Pharmacotherapy Updates, 27 November 2019. McGraw-Hill, New York, NY, 2019. AccessPharmacy. https://accesspharmacy.mhmedical.com/updatesContent.aspx?gbosid=508788§ionid=233072578
Lewis SJ, Churchwell MD. “New KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline." Pharmacotherapy Updates, 19 August 2019. McGraw-Hill, New York, NY, 2016. AccessPharmacy. http://accesspharmacy.mhmedical.com/updatesContent.aspx?gbosid=487336§ionid=224653562
Khan, AM, Lewis S. Acute Kidney Injury. PharmacyLibrary's PharmacotherapyFirst: A Multimedia Learning Resource. Washington, DC: American Pharmacists Association; 2017. http://pharmacylibrary.com/doi/full/10.21019/pharmacotherapyfirst.aki_overview
Rose J, Lewis SJ. “Antimicrobial Agents with Primary Activity against Gram-Negative Bacteria." Textbook of Critical Care. 7th Ed. Eds. Vincent JL, Abraham E, Moore FA, Kochanek PM, Fink MP. Philadelphia: ELSEVIER, 2017. 812-817. Print.
Peer Reviewed Presentations
Jang SM, Lewis SJ, Rhie JY. Probability of Target Attainment of Cephalosporines against Pseudomonas aeruginosa in Critically Ill Patients treating with Continuous Renal Replacement Therapy. The 21st Asian Conference on Clinical Pharmacy Virtual Meeting; February 11-13, 2022.
Lewis SJ, Jang SM, Rhie JY. Simulation of Antibiotic Dosing for Resistant Pathogens causing Hospital-acquired Infections in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. The 21st Asian Conference on Clinical Pharmacy Virtual Meeting; February 11-13, 2022.
Brooke D, Eid H, Lewis SJ, Richardson JL. Impact of Pharmacist Intervention to Deprescribe Inappropriate Aspirin Therapy in an Outpatient Anticoagulation Clinic at a Community Hospital. 2021 American Society of Health System Pharmacists Midyear Virtual Clinical Meeting; December 5-9, 2021.
Lewis SJ, Jang SM, Rhie JY. Meropenem and Piperacillin/tazobactam Dosing Recommendations in Asian Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Poster presented at: 2021 American College of Clinical Pharmacy Annual Virtual Meeting; October 16-19, 2021.
Lewis SJ, Mueller BA. Cefazolin Dosing Recommendations in Patients Receiving Home Hemodialysis. Poster presented at: 2021 American College of Clinical Pharmacy Annual Virtual Meeting; October 16-19, 2021.
Jang SM, Lewis SJ, Rhie JY. Probability of Target Attainment of Cefepime and Ceftazidime in Asian Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Poster presented at: 2021 American College of Clinical Pharmacy Annual Virtual Meeting; October 16-19, 2021.
Milby MN, Lewis SJ. Monte Carlo simulation to determine optimal ceftolozane/tazobactam dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. Poster presented at: 2021 American College of Clinical Pharmacy Annual Virtual Meeting; October 16-19, 2021.
Guy JW, Oestreich JH, Lewis SJ, Surowiec SM, Burkhart T, Dauterman T. Novel Approaches in Hybrid Teaching and Experiential Learning: Successes and Challenges During COVID-19. Poster session presented at: 2021 American Association of College of Pharmacy Virtual Pharmacy Education Meeting. July 19-22, 2021.
Lewis SJ, Arnes K, Oestreich JH. “Adaptation of the RAFT Activity to Enhance Student Engagement and Empathy for Complex Patient Situations." Poster session presented at: 2021 American Pharmacist Association Virtual Annual Meeting & Exposition. March 12-15, 2021.
Lofaso ME, Sember AM, Lewis SJ. Monte Carlo Simulation to Determine Optimal Extended-Infusion Cefepime Dosing in Continuous Renal Replacement Therapy with Varying Effluent Rates. Poster session presented at: 2020 American College of Clinical Pharmacy Annual Virtual Meeting; October 19-30, 2020.
Sember AM, Lofaso ME, Lewis SJ. Optimal Extended-Infusion Dosing of Ceftazidime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy with Varying Effluent Rates. Poster session presented at: 2020 American College of Clinical Pharmacy Annual Virtual Meeting; October 19-30, 2020.
Lewis SJ, Richardson J, Tanyanyiwa C. Impact of utilizing a once weekly non-infectious disease trained pharmacist on the implementation and execution of antimicrobial stewardship program at a small community hospital. 2019 American Society of Health System Pharmacists Midyear. Las Vegas, NV. December 8-12, 2019.
Bodenhorn D, Na E, Lewis SJ. Comparison of antibiotic dosing recommendations for patients with hemodialysis in drug information resources. American College of Clinical Pharmacy Annual Meeting 2019. New York, NY; October 26-29, 2019.
Gharibian KN, Lewis SJ, Heung M, Segal JH, Salama NN, Mueller BA. Telavancin pharmacokinetics in patients with chronic kidney disease receiving hemodialysis. American College of Clinical Pharmacy Annual Meeting 2016. Hollywood, FL; October 23-26, 2016.
Lewis SJ, Mueller BA. Contemporary Vancomycin Dosing in Chronic Hemodialysis (HD) Patients Does Not Meet AUC Targets: Development of a New Dosing Model Using Monte Carlo Simulation (MCS). IDWeek 2016. New Orleans, LA; October 26-30, 2016.
Chaijamorn W, Lewis SJ, Shaw AR, Mueller BA. Ceftolozane/Tazobactam Clearance During In Vitro Continuous Renal Replacement Therapy (CRRT). IDWeek 2016. New Orleans, LA; October 26-30, 2016.
Chaijamorn W, Lewis SJ, Shaw AR, Mueller BA. Monte Carlo Simulations (MCS) to Determine Optimal Levofloxacin Dosing for Gram Negative Infections in Patients Receiving SHIFT RRT. Acute Kidney Injury Continuous Renal Replacement Therapy 2016 International Conference. San Diego, CA; February 16-19, 2016.
Chaijamorn W, Lewis SJ, Shaw AR, Gharibian KN, Mueller BA. Monte Carlo Simulations (MCS) to Determine Optimal Levofloxacin Regimens for Streptococcus pneumoniae Infections in Patients Receiving SHIFT Renal Replacement Therapy. Acute Kidney Injury Continuous Renal Replacement Therapy 2016 International Conference. San Diego, CA; February 16-19, 2016.
Shaw AR, Lewis SJ, Mueller BA. Development of Ciprofloxacin Dosing Recommendations for Critically Ill Patients Receiving SHIFT Renal Replacement Therapy. Acute Kidney Injury Continuous Renal Replacement Therapy 2016 International Conference. San Diego, CA; February 16-19, 2016.
Li J, Lewis SJ, Gharibian KN, Mueller BA. Probability of Target Attainment for Gentamicin Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Acute Kidney Injury Continuous Renal Replacement Therapy 2016 International Conference. San Diego, CA; February 16-19, 2016.
Lewis SJ, Gharibian KN, Mueller BA. Use of Monte Carlo Simulation to Determine Optimal Meropenem Regimens in Patients Receiving SHIFT Renal Replacement Therapy. American Society of Nephrology Kidney Week 2015 Annual Meeting, San Diego, CA; November 5-8, 2015.
Lewis SJ, Gharibian KN, Tolwani AJ, Fissell WH, Mueller BA. Evaluation of Piperacillin/Tazobactam Regimens in Patients with SHIFT Renal Replacement Therapy. American Society of Nephrology Kidney Week 2015 Annual Meeting, San Diego, CA; November 5-8, 2015.
Gharibian KN, Lewis SJ, Mueller BA. Cefepime Dosing in Critically Ill Patients Receiving SHIFT Hemofiltration or Hemodialysis Renal Replacement Therapies. American Society of Nephrology Kidney Week 2015 Annual Meeting, San Diego, CA; November 5-8, 2015.
Gharibian KN, Lewis SJ, Mueller BA. Identification of Optimal Ceftazidime Dosing Regimens in Critically Ill Patients Receiving SHIFT Renal Replacement Therapy. American Society of Nephrology Kidney Week 2015 Annual Meeting, San Diego, CA; November 5-8, 2015.
Gharibian KN, Lewis SJ, Bull JL, Pitre J, Scoville BA, Velenosi T, Urquhart B, Perkins NC, Mueller BA. Effect of Computationally-Optimized Vibration on Clearance of Solutes During In Vitro Hemodialysis. American Society of Nephrology Kidney Week 2015 Annual Meeting, San Diego, CA; November 5-8, 2015.
Lewis SJ, Switaj L, Mueller BA. Tedizolid clearance by in-vitro continuous renal replacement therapy (CRRT) model. 2015 International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium; March 17-20, 2015.
Lewis SJ, Polso A, Lee JA, Daneshvar F, Leino A, Mueller BA. Comparison of Drug Dosing Equations for Continuous Renal Replacement Therapy. Presented at Continuous Renal Replacement Therapy 2014 International Conference. San Diego, CA; March 4-7, 2014. http://crrtonline.com/posters_2014/79- Lewis_Susan.pdf
Lewis SJ, Sahloff E, Jung R. Gender differences in virological outcome in HIV-infected patients on Highly Active Antiretroviral Therapy (HAART). 2012 American Society of Health System Pharmacists Midyear. Las Vegas, Nevada. December 2012
Grants
“Game-Based Curricular Design to Develop Health Professionals of the Future". PI: Lewis SJ, Oestreich J, Guy J. Sponsor: University of Findlay Enhanced Teaching and Scholarship Grant. 2021; $2,500 [funded]
“Penicillin Skin Testing : Comparison of Broad-Spectrum Antibiotic Use and Cost Before and After Penicillin Skin Testing Implementation". PI: Lewis SJ. Co-PIs: Richardson JL, Newmister C.
Sponsor: University of Findlay Enhanced Teaching and Scholarship Grant. 2016; $5,000 [not funded]
“Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients with Chronic Kidney Disease Stage 5." PI: Mueller BA. Co-PI: Lewis SJ. Sponsor: Theravance Biopharma, Inc. 12/30/2014 - 12/31/2016. Total Direct Costs: $178,185
“Development of Antibiotic Dosing Regimens for SHIFT Dialysis Therapy." PI: Mueller BA. Co-PI: Lewis SJ. Sponsor: NxStage Medical, Inc. 12/16/2014 - 12/15/2016. Total Direct Costs: $51,447
“Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy (CRRT): An In-Vitro Investigation" PI: Mueller BA. Co-PI: Lewis SJ. Sponsor: Merck & Co. 6/01/2015-6/01/2017. Total Direct Costs: $97,176
“Pharmacokinetics of Intradialytically Dosed Telavancin." PI: Mueller BA. Co-PI: Lewis SJ. Sponsor: Theravance Biopharma, Inc. 12/01/2014. Total Direct Costs: $321,110 [not funded]
“Tedizolid Clearance During Continuous Renal Replacement Therapy (CRRT): An In-vitro Investigation." PI: Mueller BA. Co-PI: Lewis SJ. Sponsor: Cubist Pharmaceuticals, Inc. 05/01/14 - 04/30/15. Total Direct Costs: $38,495
“Effects of Vibration on Clearance During Hemodialysis Performed with a Standard Permeability Dialyzer." PI: Mueller BA. Co-PI: Lewis SJ. Sponsor: Michigan Institute for Clinical & Health Research. 06/01/13 - 01/31/15. Total Direct Costs: $49,745